Evaluation of pharmacogenomics and hepatic nuclear imaging-related covariates by population pharmacokinetic models of irinotecan and its metabolites.

doi:10.1007/s00228-021-03206-w

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Evaluation of pharmacogenomics and hepatic nuclear imaging-related covariates by population pharmacokinetic models of irinotecan and its metabolites.

European journal of clinical pharmacology - 1 Jan 2022

Liu Zheng, Martin Jennifer H, Liauw Winston, McLachlan Sue-Anne, Link Emma, Matera Anetta, Thompson Michael, Jefford Michael, Hicks Rod J, Cullinane Carleen, Hatzimihalis Athena, Campbell Ian, Crowley Simone, Beale Phillip J, Karapetis Christos S, Price Timothy, Burge Mathew E, Michael Michael

Abstract excerpt

BACKGROUND: Body surface area (BSA)-based dosing of irinotecan (IR) does not account for its pharmacokinetic (PK) and pharmacodynamic (PD) variabilities. Functional hepatic nuclear imaging (HNI) and excretory/metabolic/PD pharmacogenomics have shown correlations with IR disposition and toxicity/efficacy. This study reports the development of a nonlinear mixed-effect population model to identify pharmacogenomic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ATP Binding Cassette Transporter, Subfamily B

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Australia

Share to Glucuronosyltransferase

Share to Irinotecan

Share to Neoplasm Metastasis

Share to Pharmacogenetics

Share to Pharmacogenomic Variants

Share to Topoisomerase I Inhibitors

Source

Open in PubMed

Identifiers

PMID: 34480602
DOI: 10.1007/s00228-021-03206-w

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evaluation of pharmacogenomics and hepatic nuclear imaging-related covariates by population pharmacokinetic models of irinotecan and its metabolites.PMID 34480602Read ↗

Pharmacogenomics and functional imaging to predict irinotecan pharmacokinetics and pharmacodynamics: the predict IR study.Semantic proximity Read ↗

Relationship of hepatic functional imaging to irinotecan pharmacokinetics and genetic parameters of drug elimination.Semantic proximity Read ↗

Pharmacokinetic and Pharmacogenetic Markers of Irinotecan Toxicity.Semantic proximity Read ↗

Integration of DNA sequencing with population pharmacokinetics to improve the prediction of irinotecan exposure in cancer patients.Semantic proximity Read ↗

Pharmacogenetics of irinotecan metabolism and transport: an update.Semantic proximity Read ↗

Highlights from the latest articles in pharmacogenomics of irinotecan/cisplatin toxicity.Semantic proximity Read ↗

Clinical and pharmacogenetic factors associated with irinotecan toxicitySemantic proximity Read ↗

OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy.Semantic proximity Read ↗

Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics.Semantic proximity Read ↗

Effect of Single Nucleotide Polymorphisms in the Xenobiotic-sensing Receptors NR1I2 and NR1I3 on the Pharmacokinetics and Toxicity of Irinotecan in Colorectal Cancer Patients.Semantic proximity Read ↗

Pharmacogenetic Pathway Analysis of IrinotecanSemantic proximity Read ↗

Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.